Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT05038592 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic Leukemia-1
Chronic Myelomonocytic Leukemia-2
Myelodysplastic/Myeloproliferative Neoplasm

Interventions

DRUG: Decitabine
BIOLOGICAL: Tagraxofusp-erzs

Sponsor

M.D. Anderson Cancer Center